247 related articles for article (PubMed ID: 24895141)
1. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension.
Sanford M
Clin Drug Investig; 2014 Jul; 34(7):521-8. PubMed ID: 24895141
[TBL] [Abstract][Full Text] [Related]
2. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
Aptel F; Choudhry R; Stalmans I
Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
[TBL] [Abstract][Full Text] [Related]
3. Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.
Harasymowycz P; Hutnik C; Rouland JF; Negrete FJM; Economou MA; Denis P; Baudouin C
Adv Ther; 2021 Jun; 38(6):3019-3031. PubMed ID: 33891269
[TBL] [Abstract][Full Text] [Related]
4. COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Kandarakis S; Papadopoulos AP; Roussopoulos G; Georgopoulos E; Chung Y; Doumazos L; Baek A; Paizi NI; Shin H; Papadopoulos PA
Expert Opin Drug Saf; 2024 Jun; 23(6):743-754. PubMed ID: 37674345
[TBL] [Abstract][Full Text] [Related]
5. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
[TBL] [Abstract][Full Text] [Related]
6. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
Wong TT; Aung T; Ho CL
Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
[TBL] [Abstract][Full Text] [Related]
7. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma.
Seong HJ; Lee K; Lee SJ; Kim S; Park JW
Korean J Ophthalmol; 2021 Jun; 35(3):235-241. PubMed ID: 34120423
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
Cucherat M; Stalmans I; Rouland JF
J Glaucoma; 2014 Jan; 23(1):e69-75. PubMed ID: 23881267
[TBL] [Abstract][Full Text] [Related]
10. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
Nagstrup AH
Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
[TBL] [Abstract][Full Text] [Related]
11. [Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study].
Denis P;
J Fr Ophtalmol; 2016 Sep; 39(7):622-30. PubMed ID: 27567675
[TBL] [Abstract][Full Text] [Related]
12. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
13. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
[TBL] [Abstract][Full Text] [Related]
15. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
16. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
[TBL] [Abstract][Full Text] [Related]
17. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
19. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.
Patel SS; Spencer CM
Drugs Aging; 1996 Nov; 9(5):363-78. PubMed ID: 8922563
[TBL] [Abstract][Full Text] [Related]
20. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
